RJ Tesi, M.D., co-founder and CEO of clinical-stage
immunology company INmune Bio (NASDAQ: INMB), was recently featured in an
interview with multimedia financial reporter Jason Lin. Among other highlights,
Dr. Tesi discusses recent company accomplishments in the interview. “Nasdaq’s
MarketSite is a premiere platform for INmune Bio to share our story with
investors and to discuss recent developments in our programs for cancer,
Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease,”
INmune co-founder and CEO Dr. RJ Tesi stated in the interview. “We hope to
continue reaching new milestones in the development of therapies that target
the innate immune system.” The company also announced today that CJ Barnum,
Ph.D., Director of Neuroscience, will be presenting on “Approaching Alzheimer’s
disease as an immunological disease: role of biomarkers” at the World
Immunotherapy Congress taking place on October 16 in Switzerland.
To view the interview, visit http://ibn.fm/298yz
To view the full press release, visit http://ibn.fm/ypk9K
About INmune Bio, Inc.
INmune Bio is a publicly traded, clinical-stage
biotechnology company focused on developing treatments that target the innate
immune system to fight disease. INmune Bio has two product platforms. The DN-TNF
product platform utilizes dominant-negative technology to selectively
neutralize soluble TNF, a key driver of innate immune dysfunction and
mechanistic target of many diseases. DN-TNF is currently being developed for
cancer (INB03), Alzheimer’s (XPro595), and NASH (NeuLiv). The Innate Immune
Priming Platform includes INKmune aimed at priming the patient’s NK cells to
eliminate minimal residual disease in patients with cancer. INmune Bio’s
product platforms utilize a precision medicine approach for the treatment of a
wide variety of hematologic malignancies, solid tumors and chronic
inflammation. For more information, visit the company’s website at www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
